Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases.
infoBristolMyers Squibb Company is a large cap stock with a total market cap of 128.60B.
infoThey trade on the NYSE and had their IPO 51 years and 2 months ago.
infoBristolMyers Squibb Company currently employs 34300 people.
infoAs of Wednesday, Aug 23 2023, BristolMyers Squibb Company’s share price is $61.56.
News Relating to BristolMyers Squibb Company
Zacks Investment Research
Bristol Myers’ (BMY) Opdivo Gets EC Nod for Label Expansion
Wednesday Aug 23 2023 at 12:47
Bristol Myers (BMY) obtains approval in the EU for Opdivo for the adjuvant treatment of adults and adolescents with stage IIB or IIC melanoma who have undergone complete resection.
InvestorPlace
3 Sorry Pharma Stocks to Sell in August Before It’s Too Late
Tuesday Aug 22 2023 at 16:38
Pharmaceutical stocks can bring you from rags to riches — and back to rags again. The truth is the innovative sector can function similarly to a lottery.
Zacks Investment Research
Bristol Myers (BMY) Announces Positive Updated NSCLC Data
Thursday Aug 17 2023 at 13:17
Bristol Myers’ (BMY) repotrectinib shows durable efficacy benefits in patients with locally advanced or metastatic ROS1-Positive non-small cell lung cancer.
CNBC Television
Pharma stocks are typically shunned by Wall St. when people feel confident about economy: Jim Cramer
Wednesday Aug 16 2023 at 19:32
‘Mad Money’ host Jim Cramer talks the Pharma industry facing off against the federal government over IRA provisions.
The Motley Fool
2 Dividend Stocks to Buy Hand Over Fist
Wednesday Aug 16 2023 at 09:53
Bristol Myers Squibb’s declining revenue growth won’t last forever. Microsoft has a strong moat and plenty of avenues for expansion.
CNBC Television
What pharma brands will be impacted by Medicare price negotiations
Monday Aug 14 2023 at 14:59
Jared Holz, Mizuho healthcare strategist, joins ‘The Exchange’ to discuss Medicare drug price negotiations, the M&A impact of government intervention into drug pricing, and more.
The Motley Fool
2 Blue Chip Dividend Stocks That Are Top Buys in August
Monday Aug 14 2023 at 14:36
Blue chip dividend stocks can be outstanding picks for investors with a long-term outlook. Abbott Laboratories and Bristol Myers Squibb are two top-shelf pharma stocks that stand out from the crowd.
Zacks Investment Research
Pharma ETFs in Focus Post Q2 Earnings
Friday Aug 11 2023 at 13:47
Second-quarter earnings beat ratio of 86.6% and revenue beat ratio of 84.9% for the healthcare sector are impressive.
CNBC Television
Final Trades: Bristol Myers, Toast & more
Thursday Aug 10 2023 at 14:11
The “Halftime Report” traders give their top picks to watch for the second half.
CNBC
These 10 medications are likely targets for Medicare price negotiations this fall
Thursday Aug 10 2023 at 13:22
It’s still unclear which drugs Medicare will select, but several companies have revealed in court filings that four of their medications are targets.
Market Watch
Bristol Myers Squibb stock extends bounce after announced $4 billion accelerated buyback agreements
Thursday Aug 10 2023 at 07:08
Shares of Bristol Myers Squibb Co. BMY, +0.76% got a 0.9% bump up in premarket trading Thursday, after the biopharmaceutical company announced $4 billion in accelerated share repurchase agreements. The ASR represents 3.2% of the company’s market capitalization of $126.64 billion as of Wednesday’s close.
The Motley Fool
Should Dividend Investors Buy Bristol Myers Stock?
Sunday Aug 06 2023 at 08:45
Deteriorating Revlimid sales weighed on second-quarter results. Still, the drugmaker offers a generous and sustainable dividend.
Zacks Investment Research
Here’s Why Investors Should Buy These 2 Medical Stocks After Earnings
Thursday Aug 03 2023 at 02:59
Following their favorable Q2 reports now looks like a good time to buy Encompass Health (EHC) and Vertex Pharmaceuticals (VRTX) stock.
Seeking Alpha
Time To Go Defensive With These ETFs
Wednesday Aug 02 2023 at 04:05
High-beta stocks have outperformed defensive stocks in the stock market recently, raising questions about the effectiveness of low-volatility and dividend growth investing. ROBECO’s research shows that low-volatility investing can significantly improve long-term performance, particularly in market environments with increased retail investor participation. Low-risk ETFs, such as healthcare names and dividend aristocrats, offer exposure to fundamentally strong factors and tend to perform well during periods of stagflation, high inflation, and decent economic growth.
InvestorPlace
Looking for a Bargain? 7 Blue-Chip Stocks to Buy That Are Down 5% in 2023
Tuesday Aug 01 2023 at 07:10
The allure of discounted blue-chip stocks shines brighter than ever amid the complex mosaic of the stock market. With the stock market witnessing a rise driven by a handful of names, the flip side reveals several stocks lagging behind indices.
MarketBeat
Here are 3 AI Drug Discovery Stocks to Put on Your Watchlist
Tuesday Aug 01 2023 at 07:01
Artificial intelligence (AI) has hit the mainstream with fervor. Specifically, generative AI has gone viral with the explosion in ChatGPT users.
Seeking Alpha
Bristol-Myers Squibb’s Bright Future Unfolds Beyond Q2 2023 Turmoil
Saturday Jul 29 2023 at 08:03
Bristol-Myers Squibb’s revenue for the second quarter of 2023 was $11.23 billion, down 0.97% from the previous quarter and 5.6% from the second quarter of 2022. Sales of Opdualag, an FDA-approved drug for treating patients with unresectable or metastatic melanoma, totaled $154 million in Q2 2023, up 165.6% from Q2 2022. On the other hand, Camzyos, a cardiac myosin inhibitor developed by MyoKardia, which Bristol-Myers Squibb acquired for $13.1 billion in 2020, is seeing strong sales.
Zacks Investment Research
Bristol-Myers (BMY) Q2 Earnings, Sales Miss, ’23 View Lowered
Thursday Jul 27 2023 at 15:28
Bristol-Myers’ (BMY) second-quarter 2023 earnings and sales miss estimates due to generic erosion for the oncology drug Revlimid. The company also cuts its forecast for 2023.
Seeking Alpha
Bristol-Myers Squibb Company (BMY) Q2 2023 Earnings Call Transcript
Thursday Jul 27 2023 at 12:37
Bristol-Myers Squibb Company (NYSE:BMY ) Q2 2023 Earnings Call Transcript July 27, 2023 8:00 AM ET Company Participants Timothy Power – VP & Head, IR Giovanni Caforio – Chairman & CEO David Elkins – EVP & CFO Christopher Boerner – EVP & Chief Commercialization Officer Adam Lenkowsky – Chief Commercialization Officer Samit Hirawat – EVP & Chief Medical Officer, Global Drug Development Conference Call Participants Chris Shibutani – Goldman Sachs Evan Seigerman – BMO Capital Markets Geoff Meacham – Bank of America Terence Flynn – Morgan Stanley Chris Schott – JPMorgan Seamus Fernandez – Guggenheim Carter Gould – Barclays Timothy Anderson – Wolfe Research Steve Scala – TD Cowen Matthew Phipps – William Blair David Risinger – Leerink Partners Mohit Bansal – Wells Fargo Yihan Li – UBS Dane Leone – Raymond James Olivia Brayer – Cantor Fitzgerald Operator Good morning, everyone. Welcome to the Bristol-Myers Squibb Second Quarter 2023 Earnings Conference Call.
Zacks Investment Research
Compared to Estimates, Bristol Myers (BMY) Q2 Earnings: A Look at Key Metrics
Thursday Jul 27 2023 at 11:42
The headline numbers for Bristol Myers (BMY) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
The Motley Fool
2 Dirt Cheap Dividend Stocks to Buy Right Now
Thursday Jul 27 2023 at 09:37
Bristol Myers’ innovative wheel should keep revenue moving in the right direction. Pfizer’s success in the coronavirus market is helping fund other potential products.
Barrons
Bristol Myers Slashes Forecast on Tumbling Revlimid Sales
Thursday Jul 27 2023 at 08:13
Cancer-fighting drugs Revlimid and Pomalyst drive a sales shortfall in the second quarter.
Market Watch
Bristol Myers stock takes a hit from earnings miss and lower outlook amid disappointing Revlimid sales
Thursday Jul 27 2023 at 07:17
Shares of Bristol Myers Squibb Co. BMY, -0.56% shed 2.2% in premarket trading Thursday, after the drugmaker missed second-quarter earnings expectations and cut its full-year outlook, amid a more rapid than expected decline in sales of its cancer treatment Revlimid. Net income rose to $2.07 billion, or 99 cents a share, from $1.42 billion, or 66 cents a share, in the year-ago period.
Reuters
Bristol Myers sales fall, cuts 2023 forecast as drugs face competition
Thursday Jul 27 2023 at 07:02
Drugmaker Bristol Myers Squibb said on Thursday its second-quarter sales fell more than expected and cut its full-year forecast as two of its top drugs, blood cancer treatment Revlimid and blood thinner Eliquis, face generic competition.
Zacks Investment Research
Bristol-Myers (BMY) to Report Q2 Earnings: What’s in Store?
Tuesday Jul 25 2023 at 13:08
Investors are likely to focus on the demand for Eliquis and Opdivo along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q2 results.
The Motley Fool
2 Cheap High-Yield Dividend Stocks to Buy Now
Tuesday Jul 25 2023 at 11:15
Many high-yielding stocks are either too risky or too expensive. Amgen and Bristol Myers Squibb offer above-average dividend yields, attractive valuations, and a reasonable margin of safety.
Seeking Alpha
Bristol-Myers Squibb Is A Buy At Current Support (Technical Analysis)
Sunday Jul 23 2023 at 07:56
Bristol-Myers Squibb Company (BMY) is a promising investment opportunity due to its strong presence in oncology and immunology, and its robust pipeline of compounds in development. The stock price of BMY demonstrates a strong bullish trend, suggesting a promising buying opportunity.
Seeking Alpha
Bristol Myers Squibb: The Gift Has Arrived
Sunday Jul 23 2023 at 01:07
Bristol-Myers Squibb is expected to report its Q2 results on July 27, with market sentiments highly pessimistic, heading into its earnings release. The company faces revenue challenges due to the loss of exclusivity for Revlimid. I gleaned that the market has likely reflected significant headwinds on BMY’s ability to recover. BMY’s sentiments have likely reached peak pessimism, auguring well for its upcoming earnings. Analysts are also pessimistic, lowering the bar for BMY to clear.
InvestorPlace
The 3 Most Undervalued Pharma Stocks to Buy Now: July 2023
Friday Jul 21 2023 at 15:31
Pharma stocks experienced an abysmal first half due to various factors. Rotation from defensive to cyclical sectors, drug price negotiations and upcoming patent cliffs have muddied the outlook.
Zacks Investment Research
Bristol Myers Squibb (BMY) Earnings Expected to Grow: Should You Buy?
Thursday Jul 20 2023 at 11:26
Bristol Myers (BMY) doesn’t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BristolMyers Squibb Company Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
BristolMyers Squibb Company’s Altman Z-score is 2.62 which is in the gray zone. This indicates a level of ambiguity where further analyses are needed to evaluate the company’s financial stability accurately.
Derived from SEC.GOV filing dataopen_in_new
BristolMyers Squibb Company Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, 1 insider has sold $44.75K of common stock in BristolMyers Squibb Company on the stock market with no insider buying.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
BristolMyers Squibb Company’s Income Quality of 1.49 is greater than its Industry Group of 0.69 (115.9% greater)
BristolMyers Squibb Company’s Income Quality of 1.49 is greater than its Major Industry Group of 0.71 (109.9% greater)
BristolMyers Squibb Company’s Income Quality of 1.49 is greater than its Sector of 0.75 (98.7% greater)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
BristolMyers Squibb Company’s Current Ratio of 1.39 is lower than its Industry Group of 4.76 (-70.8% lower)
BristolMyers Squibb Company’s Current Ratio of 1.39 is lower than its Major Industry Group of 4.32 (-67.8% lower)
BristolMyers Squibb Company’s Current Ratio of 1.39 is lower than its Sector of 2.6 (-46.5% lower)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (16.15 & -1.27)
Cannot compare a negative PE Ratio (16.15 & -1.1)
Cannot compare a negative PE Ratio (16.15 & -0.4)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
BristolMyers Squibb Company’s PB Ratio of 4.02 is greater than its Industry Group of 1.34 (200.0% greater)
BristolMyers Squibb Company’s PB Ratio of 4.02 is greater than its Major Industry Group of 1.4 (187.1% greater)
BristolMyers Squibb Company’s PB Ratio of 4.02 is greater than its Sector of 1.62 (148.1% greater)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
BristolMyers Squibb Company’s ROE of 0.25 is greater than its Industry Group of -0.44 (156.8% greater)
BristolMyers Squibb Company’s ROE of 0.25 is greater than its Major Industry Group of -0.38 (165.8% greater)
BristolMyers Squibb Company’s ROE of 0.25 is greater than its Sector of -0.03 (933.3% greater)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
BristolMyers Squibb Company’s ROCE of 0.16 is greater than its Industry Group of -0.42 (138.1% greater)
BristolMyers Squibb Company’s ROCE of 0.16 is greater than its Major Industry Group of -0.37 (143.2% greater)
BristolMyers Squibb Company’s ROCE of 0.16 is greater than its Sector of -0.04 (500.0% greater)
Derived from SEC.GOV filing dataopen_in_new